Navigation Links
Escalon(R) Reports First Quarter Fiscal 2009 Results
Date:11/13/2008

ct revenue $8,669,165 $6,833,350

Other revenue 28,278 59,921

Revenues, net 8,697,443 6,893,271

Costs and expenses:

Cost of goods sold 4,844,140 3,922,586

Marketing, general and administrative 3,276,317 2,939,908

Research and development 1,046,165 923,361

Total costs and expenses 9,166,622 7,785,855

Income (loss) from operations (469,180) (892,584)

Other (expense) and income:

Equity in Ocular Telehealth Management, LLC (21,000) (34,111)

Interest income 47,526 101,697

Interest expense (9,408) (3,793)

Total other income 17,118 63,793

Net (loss) before taxes (452,062) (828,791)

Provision for income taxes 28,800 0

Net (loss) $(480,862) $(828,791)

Basic net (loss) per share $(0.07) $(0.13)

Diluted net income (loss) per share $(0.07) $(0.13)

Weighted average shares - basic 6,413,930 6,388,086

Weighted average shares - diluted 6,413,930 6,388,086

ESCALON MEDICAL CORP. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

September 30, June 30,

2008 2008

Cash and cash equivalents $2,310,537 $3,708,456

Total assets 30,676,515 31,896,020

Total current liab
'/>"/>

SOURCE Escalon Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Escalon(R) Receives FDA 510(k) Clearance to Market the LIASYS(TM) Clinical Chemistry and Immunoturbidimetric Analyzer
2. Escalon(R) Enhances Position Within IVD Reagent Market with Strategic Acquisition of JAS Diagnostics
3. Escalon(R) Announces China Registration for Sonomed PacScan(R) and E/Z-Scan(R) Series of A-scan, Pachymeter and B-Scan Systems
4. Escalon(R) Announces Executive Promotions
5. Escalon(R) Announces FDA 510(K) Clearance for D3 Hematology System
6. Escalon(R) Reports First Quarter Fiscal 2008 Results
7. Escalon(R) Reports Financial Results for 2007 Fiscal Year
8. PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer
9. PA Health Department Reports Southeast Regions First Lab-Confirmed Influenza Case of the Season
10. CDC Reports Drop in Adult Smoking, But Death Toll and Health Costs Are Still Growing; Congress, States Should Implement Proven Solutions
11. Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... SUNNYVALE, Calif., Dec. 6 Pharmacyclics, Inc. ... from a Phase I/II study showing safety and ... non-Hodgkin,s Lymphoma (NHL) treated with its HDAC inhibitor ... presented today at the 51st ASH Annual Meeting ... 2726). ,, PCI-24781 is an oral pan-HDAC ...
(Date:12/6/2009)... growth factor, researchers say , , SUNDAY, Dec. 6 ... from the main tumor to other parts of the ... TGFb, which may prove a promising target for new ... , Previous studies have shown that TGFb (transforming growth ... this new study, a team from Cancer Research UK ...
(Date:12/6/2009)... 6 Sickle cell disease, a condition ... is one of the most common genetic blood ... including more than 70,000 Americans.(1) Research presented today ... Society of Hematology highlights intriguing studies on the ... children with this blood disorder, evaluations of both ...
(Date:12/6/2009)... cooperation with the Greater VA Healthcare System in West Los Angeles, ... expected to soar to more than 5,000 veterans, active military personnel ... ... 6, 2009 -- Volunteer organizations and members of the community, in ... will once again create a holiday party. This year,s attendance is ...
(Date:12/5/2009)... ,, What: Cuts for a Cause ,, ... against cancer and other terminal illnesses affecting children. All proceeds ... Jude Children,s Research Hospital. Guests will enjoy complimentary beverages and ... Vietnamese restaurant in Falls Church for all guests. Hoa Lai, ...
Breaking Medicine News(10 mins):Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 2Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 3Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 4Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 5Health News:Breast Cancer's Spread Now Better Understood 2Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 2Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 3Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 4Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 5Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 6Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 7Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 8Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 9Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 2Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 3
... news with one more ailment added to its list of ... enhanced risk of colon cancer. // ,Scientists from ... between obesity and cancer of the colon. According to scientists, ... which induces growth of colon cancers. , ,Cancerous ...
... Experts are describing as a “ U-turn of dramatic proportions”, ... women can in fact prevent// them from the risks of ... Journal of the American Medical Association shows that hormone replacement ... not put such women at higher risks of heart attacks ...
... come out with a possible herbal cure for urinary track// ... Duke University Medical Center found that the herb ... can significantly reduce UTI as well as help antibiotics kill ... ,The National Kidney and Urologic Diseases Information Clearinghouse (NKUDIC) says ...
... will soon start an integrated trauma care facility to ... //to patients on way to a hospital from an ... of Physicians of Indian Origin (AAPI), the emergency medical ... fully equipped ambulances within minutes of an accident., ...
... Obese people face greater risk of developing colon cancer, the ... ,The fat cells in the body of obese people produce ... faster. The more fat cells a person has, the more ... in the British Journal of Surgery. ,A colon ...
... have announced that a first line phase III study ... chances among cancer patients with recurrent and metastatic squamous ... ,Worldwide SCCHN is the most common form of ... of all patients are diagnosed with advanced disease. ...
Other Medicine News:Health News:Hormone Replacement Therapy- Not A Fallen Angel 2Health News:Ancient Indian Herb May Prove Cure For Recurrent UTI 2Health News:Integrated Trauma Care Facility in Mumbai 2Health News:Integrated Trauma Care Facility in Mumbai 3Health News:A New Erbitux Combo Shows Promise in treatment 2
(Date:12/4/2009)... U.S. Food and Drug Administration (FDA) today approved Zyprexa® ... treatment of schizophrenia and manic or mixed episodes associated ... old. ,, The updated Zyprexa label states that ... weight gain and hyperlipidemia in adolescents compared to adults ...
(Date:12/4/2009)... ,, PHILADELPHIA, Dec. 4 Teamster members employed by ... hard at work educating the public about the unfair ... Philadelphia,s blood supply at risk. More than 100 ... line yesterday when their issues were ignored by their ...
(Date:12/4/2009)... Inc. (OTC Bulletin Board: OXBT) today announced that the ... II-b, dose escalation, clinical trial in Switzerland for use ... is the Company,s perfluorocarbon (PFC) therapeutic oxygen carrier. ,, ... outcome of patients with severe TBI. We hope to ...
Breaking Medicine Technology:FDA Approves Lilly's Zyprexa for Two Adolescent Indications 2FDA Approves Lilly's Zyprexa for Two Adolescent Indications 3FDA Approves Lilly's Zyprexa for Two Adolescent Indications 4FDA Approves Lilly's Zyprexa for Two Adolescent Indications 5FDA Approves Lilly's Zyprexa for Two Adolescent Indications 6FDA Approves Lilly's Zyprexa for Two Adolescent Indications 7Striking Red Cross Workers Raise Public Awareness of Unsafe Working Conditions 2Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland 2Science study 3A Teacher participation in Columbia program improves student achievement in science 59663 1Science study 3A Teacher participation in Columbia program improves student achievement in science 59663 2Science study 3A Teacher participation in Columbia program improves student achievement in science 59663 3Science study 3A Teacher participation in Columbia program improves student achievement in science 59663 4Yerkes researchers present at 39th Annual Society for Neuroscience Conference 59660 1Yerkes researchers present at 39th Annual Society for Neuroscience Conference 59660 2Yerkes researchers present at 39th Annual Society for Neuroscience Conference 59660 3Yerkes researchers present at 39th Annual Society for Neuroscience Conference 59660 4Yerkes researchers present at 39th Annual Society for Neuroscience Conference 59660 5Fish vision discovery makes waves in natural selection 10401 1Fish vision discovery makes waves in natural selection 10401 2Fish vision discovery makes waves in natural selection 10401 3
... 10, 2007 - Inotek,Pharmaceuticals Corporation announced today the ... showing that the,administration of a poly(ADP-Ribose) polymerase (PARP) ... of certain brain,cells following a stroke. PARP is ... DNA via the activation and recruitment of DNA,repair ...
... Unite to Help Educate on Good,Diabetes Management and ... Problems, SEATTLE, April 10, 2007 /PRNewswire/ -- A ... type 2 diabetes,complications shows that an estimated three ... diabetes have at least one of the other,serious ...
Other Medicine Technology:Inotek Pharmaceuticals Announces Publication of Animal Data from,Study of PARP Inhibition as Potential Preventative of Brain Injury,Following Stroke 2Inotek Pharmaceuticals Announces Publication of Animal Data from,Study of PARP Inhibition as Potential Preventative of Brain Injury,Following Stroke 3First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 2First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 3First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 4First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 5First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 6First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America 7
Small, removable blades, length 178 mm, (7"). Function: tissue retracting....
... reagents for the quantitative determination of ... as well as heparin- and EDTA- ... using the BN Systems. In acute ... number of plasma proteins, including C-reactive ...
Peapod Rongeur, 5.5 length 140 mm....
Suitable for children and adults. New mechanical design of the skull pin holder and the clamp base ensures improved rigid skull fixation....
Medicine Products: